SC-4289
 | |
| Clinical data | |
|---|---|
| Other names | 6-[1'-Ethyl-2',2'-dimethyl-3'-hydroxy]propyl-β-naphthol-2-benzyl ether[1] |
| Routes of administration | By mouth |
| Drug class | Nonsteroidal estrogen |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C24H28O2 |
| Molar mass | 348.486 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
SC-4289 is a synthetic nonsteroidal estrogen which, along with mytatrienediol (SC-6924; Manvene, Anvene), was developed in the late 1950s as a potential treatment for atherosclerosis in men but was never marketed.[2][3]
The chemical structure of SC-4289 is the same as for methallenestril but differs in that it is the benzyl ether and not the methyl ether.
SC-4289 makes an appearance in the allenestrol patent,[4] as well as a stand-alone compound in:[5]
References
[edit]- ↑ Berichte über die gesamte Physiologie und experimentelle Pharmakologie. Springer-Verlag. 1958. p. 332,378.
- 1 2 Robinson, R. W., Cohen, W. D., & Higano, N. (1956, January). Serum lipid and estrogenic effects of two new „weak estrogens“ in male patients with coronary atherosclerosis. In Circulation (Vol. 14, No. 3, pp. 489-490). 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106: LIPPINCOTT WILLIAMS & WILKINS. http://circ.ahajournals.org/content/circulationaha/14/3/local/back-matter.pdf
- ↑ DAVIS FW, SCARBOROUGH WR, MASON RE, SINGEWALD ML, BAKER BM (1958). "Experimental hormonal therapy of atherosclerosis: preliminary observations on the effects of two new compounds". Am. J. Med. Sci. 235 (1): 50–9. doi:10.1097/00000441-195801000-00006. PMID 13487586. S2CID 762067.
- ↑ Raymond M Dodson & Paul B Sollman, U.S. patent 3,014,076 (1961 to GD Searle LLC).
- ↑ Raymond M Dodson & Paul B Sollman, U.S. patent 2,831,887 (1958 to GD Searle LLC).
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by adding missing information. |